Home Cart Sign in  
Chemical Structure| 124431-80-7 Chemical Structure| 124431-80-7
Chemical Structure| 124431-80-7
Product Citations

Alternative Products

Product Details of [ CGS 21680 HCl ]

CAS No. :124431-80-7
Formula : C23H30ClN7O6
M.W : 535.98
SMILES Code : O=C(O)CCC1=CC=C(CCNC2=NC(N)=C3N=CN([C@@H]4O[C@H](C(NCC)=O)[C@@H](O)[C@H]4O)C3=N2)C=C1.[H]Cl
Synonyms :
CGS 21680 (hydrochloride); CGS 21680 Hydrochloride
MDL No. :MFCD00078573
InChI Key :QPHVMNOEKKJYJO-MJWSIIAUSA-N
Pubchem ID :10256643

Safety of [ CGS 21680 HCl ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of [ CGS 21680 HCl ]

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
human neutrophils 0.01 - 1 µM 10 minutes CGS 21680 accelerated the resequestration of cytosolic calcium in FMLP-activated neutrophils and suppressed the production of oxidants and release of elastase. PMC1572119
thymocytes 300 nM 16 hours To evaluate the cytotoxicity of CGS 21680 on thymocytes, results showed that CGS 21680 induced 7-15% thymocyte death. PMC1572291
thymocytes 1 µM 16 hours To evaluate the cytotoxicity of CGS 21680 on thymocytes, results showed that CGS 21680 induced 7-15% thymocyte death. PMC1572291
Mouse cortical membranes 0.1–20 nM 4 hours To investigate the binding characteristics of CGS 21680 in mouse cortical membranes, results showed that the binding of CGS 21680 was significantly reduced in adenosine A1 receptor knockout mice. PMC1574266
thymocytes 1 µM 6 days CGS 21680 did not exhibit lymphotoxicity in long-term in vitro assays, and thymocyte survival was unaffected. PMC1572291

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Rats Acute heart failure model Intravenous infusion 0.1, 0.3 and 1.0 mg/kg/min 15 minutes To assess the effects of CGS 21680 on cardiac output and vascular resistance in rats with acute heart failure. Results showed that CGS 21680 at the highest dose significantly reduced blood pressure, arterial resistance, and left ventricular end-diastolic pressure, and significantly increased cardiac output and heart rate. PMC1565321
NMRI mice DSS-induced colitis model Intraperitoneal injection 0.5 mg/kg/day Once daily for 10 days CGS 21680 failed to ameliorate DSS-induced colitis symptoms, including weight loss, colon shortening, incidence of rectal bleeding, and levels of inflammatory cytokines. PMC2225471
Rats Schizophrenia model Intraperitoneal injection 0.03 or 0.09 mg/kg Once daily for 8 days CGS 21680 alleviated the enhanced nicotine conditioned place preference (CPP) produced by NQ treatment and reduced nicotine CPP in male control rats but not in female control rats. PMC9199013
Mice STZ-induced type 1 diabetes model intravenous injection 0.5 mg/kg single dose Enhanced coronary flow response to CGS 21680 in diabetic mice PMC4729563

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.33mL

1.87mL

0.93mL

18.66mL

3.73mL

1.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories